OnKure Therapeutics, Inc. Class A OKUR 深 沪
等待开盘 07-23 09:30:00 美东时间
4.32
+0.150
+3.60%
华盛通- 最 高4.38
- 今 开4.14
- 成交量 17.07万股
- 最 低 4.10
- 昨 收 4.17
- 总市值 17.45万
- 52周最高 5.38
- 市盈率 静 --
- 换手率 0.42%
- 52周最低 1.91
- 委 比 -10.74%
- 总股本 4.04万
- 历史最高 19.9992
- 量 比 1.76
- 振 幅 6.71%
- 历史最低 1.70
- 每 手 1
- 风险率 0.80%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | 伯恩斯坦上调Robinhood目标价从130美元升至160美元；纽约梅隆银行、Datadog、五三银行、旅行者财产险集团获多家机构上调评级
今日重点评级关注：Needham：维持Immuneering"买入"评级，目标价从11美元升至18美元；富瑞：维持塞德斯医疗"买入"评级，目标价从90美元升至100美元
07-21 11:36
HC Wainwright & Co. Maintains Buy on OnKure Therapeutics, Lowers Price Target to $21
HC Wainwright & Co. analyst Robert Burns maintains OnKure Therapeutics (NASDAQ:OKUR) with a Buy and lowers the price target from $27 to $21.
07-20 23:52
OnKure Therapeutics shares are trading lower after the company reported worse-than-expected Q1 EPS results.
OnKure Therapeutics shares are trading lower after the company reported worse-t...
05-06 23:23
OnKure Therapeutics Q1 EPS $(1.11) Misses $(0.64) Estimate
OnKure Therapeutics (NASDAQ:OKUR) reported quarterly losses of $(1.11) per share which missed the analyst consensus estimate of $(0.64) by 73.44 percent. This is a 6.72 percent increase over losses of $(1.19) per share
05-06 04:39
OnKure Therapeutics Enters Into Securities Purchase Agreement For Private Placement Raising Gross Proceeds Of ~$150M
-- Financing led by Access Biotechnology with participation from new and existing investors-- Financing to support advancement of two next-generation PI3Kα pan-mutant inhibitors for breast cancer and vascular anomalies –
03-27 20:12
美股大行评级 | 能源股获大行青睐！美国铝业、康索尔能源、康菲石油、EOG能源等获上调目标价；多只航空股遭下调目标价
今日重点评级关注：HC Wainwright & Co.：维持Altimmune"买入"评级，目标价从12美元升至25美元；BTIG：维持Jade Biosciences"买入"评级，目标价从28美元升至39美元
03-17 11:45
Micron To Rally More Than 23%? Here Are 10 Top Analyst Forecasts For Monday
Top analysts updated ratings for MU, EPAM, WLTH, OKUR, BLDR, DMRC, JBIO, CRCL. See changes and ratings on analyst ratings page.
03-16 20:12
'[HC Wainwright & Co. Maintains Buy on OnKure Therapeutics, Lowers Price Target to $27
HC Wainwright & Co. analyst Robert Burns maintains OnKure Therapeutics (NASDAQ:OKUR) with a Buy and lowers the price target from $34 to $27.
03-16 19:27
OnKure Therapeutics Q4 EPS $(0.99) Misses $(0.75) Estimate
OnKure Therapeutics (NASDAQ:OKUR) reported quarterly losses of $(0.99) per share which missed the analyst consensus estimate of $(0.75) by 32 percent. This is a 27.74 percent increase over losses of $(1.37) per share
03-13 04:16
HC Wainwright & Co. Reiterates Buy on OnKure Therapeutics, Maintains $34 Price Target
HC Wainwright & Co. analyst Robert Burns reiterates OnKure Therapeutics (NASDAQ:OKUR) with a Buy and maintains $34 price target.
2025-08-26 22:34
